Press Release
Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology
March 3, 2017
Barcelona (Catalonia, Spain), March 7, 2017. Ability Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, announced the sponsorship of the of 37th National Meeting of the Spanish Society of Pharmacology (SEF). The Meeting will be held in Barcelona from Sunday 18th to Wednesday 21th June 2017, with the British Pharmacological Society (BPS) as the main guest (http://www.sef2017.com).
This meeting will display the world class research carried out not only by SEF and BPS members but also by researchers worldwide whose investigation revolves around the pharmacology field. The programme combines plenary lectures, symposia, oral presentations and posters, to stimulate the scientific discussion as well as to set new collaborations and research opportunities especially for young researchers.
Dr. José Alfón, the VP of research and developmend of Ability Pharma, will be opening the Session 14 (Pharmacology of Anti-Cancer Drugs) on Wednesday 21th June, presenting our main project ABTL0812, an autophagy-anticancer drug in Phase II clinical trials.
This meeting will display the world class research carried out not only by SEF and BPS members but also by researchers worldwide whose investigation revolves around the pharmacology field. The programme combines plenary lectures, symposia, oral presentations and posters, to stimulate the scientific discussion as well as to set new collaborations and research opportunities especially for young researchers.
Dr. José Alfón, the VP of research and developmend of Ability Pharma, will be opening the Session 14 (Pharmacology of Anti-Cancer Drugs) on Wednesday 21th June, presenting our main project ABTL0812, an autophagy-anticancer drug in Phase II clinical trials.
LATEST NEWS
09.09.2024
Press Release
IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer + info
30.07.2024
Press Release
AbilityPharma receives WHO approval for its ABTL0812 anticancer drug to be named IBRILATAZAR + info
16.07.2024
Press Release
AGC Pharma Chemicals and AbilityPharma work together to produce innovative treatment for pancreatic cancer + info
11.03.2024
Press Release
AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
02.06.2023
Press Release
Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022
Press Release
AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022
Press Release
AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022
Press Release
AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info